These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22899397)

  • 1. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
    Moghaddam B; Krystal JH
    Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic theories of schizophrenia.
    Javitt DC
    Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
    Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    Jentsch JD; Roth RH
    Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?
    Adell A; Jiménez-Sánchez L; López-Gil X; Romón T
    Schizophr Bull; 2012 Jan; 38(1):9-14. PubMed ID: 21965469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antischizophrenic activity independent of dopamine D2 blockade.
    Kalkman HO
    Expert Opin Ther Targets; 2002 Oct; 6(5):571-82. PubMed ID: 12387681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.
    Krystal JH; Anand A; Moghaddam B
    Arch Gen Psychiatry; 2002 Jul; 59(7):663-4. PubMed ID: 12090822
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
    Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
    Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
    Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptor and schizophrenia: a brief history.
    Coyle JT
    Schizophr Bull; 2012 Sep; 38(5):920-6. PubMed ID: 22987850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
    Cascella NG; Macciardi F; Cavallini C; Smeraldi E
    J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.